These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 25337559)

  • 21. Proteomic Biomarkers for the Detection of Endometrial Cancer.
    Njoku K; Chiasserini D; Whetton AD; Crosbie EJ
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31623106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of Epigenetic Drug Targeting of Heterogenous Tumor Cell Fractions Using Potential Biomarkers of Response in Ovarian Cancer.
    Singh AK; Chandra N; Bapat SA
    Clin Cancer Res; 2015 Nov; 21(22):5151-63. PubMed ID: 26130461
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular Mechanism of Gene Mutations and Potential Therapeutic Targets in Ovarian Cancer.
    Guo T; Dong X; Xie S; Zhang L; Zeng P; Zhang L
    Cancer Manag Res; 2021; 13():3081-3100. PubMed ID: 33854378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An overview of biomarkers for the ovarian cancer diagnosis.
    Zhang B; Cai FF; Zhong XY
    Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):119-23. PubMed ID: 21632171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Biomarkers for personalized oncology: recent advances and future challenges.
    Kalia M
    Metabolism; 2015 Mar; 64(3 Suppl 1):S16-21. PubMed ID: 25468140
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarkers of ovarian tumours.
    Rapkiewicz AV; Espina V; Petricoin EF; Liotta LA
    Eur J Cancer; 2004 Nov; 40(17):2604-12. PubMed ID: 15541961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.
    El Bairi K; Kandhro AH; Gouri A; Mahfoud W; Louanjli N; Saadani B; Afqir S; Amrani M
    Cell Oncol (Dordr); 2017 Apr; 40(2):105-118. PubMed ID: 27981507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proteogenomic strategies for identification of aberrant cancer peptides using large-scale next-generation sequencing data.
    Woo S; Cha SW; Na S; Guest C; Liu T; Smith RD; Rodland KD; Payne S; Bafna V
    Proteomics; 2014 Dec; 14(23-24):2719-30. PubMed ID: 25263569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cytogenetics and Cytogenomics Evaluation in Cancer.
    Ribeiro IP; Melo JB; Carreira IM
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547595
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostate cancer epigenetic biomarkers: next-generation technologies.
    Valdés-Mora F; Clark SJ
    Oncogene; 2015 Mar; 34(13):1609-18. PubMed ID: 24837368
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genotypic and phenotypic biomarker profiles for individual risk assessment and cancer detection (lessons from bladder cancer risk assessment in symptomatic patients and workers exposed to benzidine).
    Hemstreet GP; Wang W
    Front Biosci; 2004 Sep; 9():2671-9. PubMed ID: 15358590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ovarian cancer biomarkers: current state and future implications from high-throughput technologies.
    Leung F; Diamandis EP; Kulasingam V
    Adv Clin Chem; 2014; 66():25-77. PubMed ID: 25344985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Proteomic profiling in ovarian cancer.
    Kim G; Minig L; Kohn EC
    Int J Gynecol Cancer; 2009 Dec; 19 Suppl 2(Suppl 2):S2-6. PubMed ID: 19955909
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Integrated proteomic analysis of human cancer cells and plasma from tumor bearing mice for ovarian cancer biomarker discovery.
    Pitteri SJ; JeBailey L; Faça VM; Thorpe JD; Silva MA; Ireton RC; Horton MB; Wang H; Pruitt LC; Zhang Q; Cheng KH; Urban N; Hanash SM; Dinulescu DM
    PLoS One; 2009 Nov; 4(11):e7916. PubMed ID: 19936259
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?
    Nossov V; Amneus M; Su F; Lang J; Janco JM; Reddy ST; Farias-Eisner R
    Am J Obstet Gynecol; 2008 Sep; 199(3):215-23. PubMed ID: 18468571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention and early detection of ovarian cancer: mission impossible?
    Bast RC; Brewer M; Zou C; Hernandez MA; Daley M; Ozols R; Lu K; Lu Z; Badgwell D; Mills GB; Skates S; Zhang Z; Chan D; Lokshin A; Yu Y
    Recent Results Cancer Res; 2007; 174():91-100. PubMed ID: 17302189
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarkers for screening, diagnosis, and monitoring of ovarian cancer.
    Kobayashi E; Ueda Y; Matsuzaki S; Yokoyama T; Kimura T; Yoshino K; Fujita M; Kimura T; Enomoto T
    Cancer Epidemiol Biomarkers Prev; 2012 Nov; 21(11):1902-12. PubMed ID: 22962405
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Applications of Proteomics in Ovarian Cancer: Dawn of a New Era.
    Ghose A; Gullapalli SVN; Chohan N; Bolina A; Moschetta M; Rassy E; Boussios S
    Proteomes; 2022 May; 10(2):. PubMed ID: 35645374
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancer.
    Tamir A; Gangadharan A; Balwani S; Tanaka T; Patel U; Hassan A; Benke S; Agas A; D'Agostino J; Shin D; Yoon S; Goy A; Pecora A; Suh KS
    J Ovarian Res; 2016 Mar; 9():20. PubMed ID: 27036110
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discover the molecular biomarker associated with cell death and extracellular matrix module in ovarian cancer.
    Liu Q; Guo J; Cui J; Wang J; Yi P
    Biomed Res Int; 2015; 2015():735689. PubMed ID: 25861644
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.